How to Get Dayvigo (Lemborexant) in Washington State

What Is Dayvigo and Why Washington Prescribers Use It

Dayvigo is the brand name for lemborexant, a dual orexin receptor antagonist approved by the FDA in December 2019 for adults with insomnia characterized by difficulty falling asleep, staying asleep, or both. Unlike older sedative-hypnotics, lemborexant works by blocking orexin OX1R and OX2R receptors, reducing wakefulness signals rather than broadly suppressing the central nervous system. Washington-based clinicians increasingly prefer this mechanism because the risk profile for next-morning impairment and physical dependence differs from that of benzodiazepine receptor agonists. FDA approval for Dayvigo is documented on the agency's drug label database.

The Orexin Mechanism in Plain Language

Orexin neuropeptides (also called hypocretin) keep you awake. When lemborexant occupies both orexin receptors competitively, the brain receives fewer "stay awake" signals, allowing natural sleep pressure to take over. Research published in Sleep Medicine Reviews outlines this receptor pharmacology in detail.

This approach differs from gamma-aminobutyric acid (GABA) potentiation used by zolpidem or eszopiclone, which is why lemborexant does not carry the same FDA boxed warning for complex sleep behaviors seen with non-benzodiazepine hypnotics, though the drug does carry its own labeling for CNS depression and impaired driving. The prescribing information is available on FDA's access data portal.

Key Efficacy Data from SUNRISE-1

The key phase 3 trial, SUNRISE-1 (N=1,006 adults), compared lemborexant 5 mg and 10 mg against placebo and zolpidem extended-release 6.25 mg over six months. At month one, lemborexant 10 mg reduced subjective sleep onset latency by a mean of 27.2 minutes versus 17.0 minutes for zolpidem ER (P<0.001 vs. Zolpidem ER). Lemborexant also outperformed zolpidem ER on sleep efficiency through the full six months. The SUNRISE-1 results were published in JAMA Network Open in 2019.

The companion SUNRISE-2 trial (N=949) evaluated lemborexant over 12 months and demonstrated sustained reductions in wake after sleep onset, with no evidence of rebound insomnia upon discontinuation. SUNRISE-2 data are indexed on PubMed.

Washington State Telehealth Rules for Controlled Substance Prescribing

Washington permits telehealth prescribing of Schedule IV controlled substances, including lemborexant, under specific conditions codified in the Washington State Telehealth laws and the federal Ryan Haight Online Pharmacy Consumer Protection Act. Patients do not need a prior in-person visit for an initial lemborexant prescription if the prescriber conducts a synchronous audio-video evaluation. Audio-only visits are generally insufficient for a new controlled-substance prescription under current Washington Medical Commission guidance.

What the Telehealth Visit Must Include

A compliant Washington telehealth evaluation for insomnia covers: a structured sleep history (duration, frequency, daytime impairment), screening for obstructive sleep apnea using validated tools such as the STOP-BANG questionnaire, medication and substance review, and documentation of why pharmacological treatment is appropriate. The American Academy of Sleep Medicine publishes clinical practice guidelines for insomnia evaluation that most Washington telehealth providers follow.

Provider Types Allowed to Prescribe

Washington State law authorizes the following licensed professionals to prescribe Schedule IV controlled substances:

• Medical doctors (MD)
• Doctors of osteopathic medicine (DO)
• Nurse practitioners (ARNP in Washington) with prescriptive authority
• Physician assistants (PA-C) with prescriptive authority

All must hold a current DEA registration with Schedule IV authority. Washington does not require a physician co-signature for NP or PA prescriptions when the provider has independent prescriptive authority, which most Washington ARNPs hold after completing their post-graduate requirements. Washington State nursing practice act guidance is maintained by the Washington State Department of Health.

Step-by-Step: How to Get a Dayvigo Prescription in Washington

Most Washington patients complete the following process in under two weeks from first contact to dispensed medication.

Step 1: Choose a Prescriber or Telehealth Platform

Identify a Washington-licensed prescriber. Options include your primary care provider, a board-certified sleep medicine physician, a psychiatrist, or a telehealth platform licensed in Washington that offers sleep care. Confirm the provider holds DEA Schedule IV prescribing authority before booking.

Step 2: Complete a Synchronous Video Evaluation

Attend the telehealth visit via secure audio-video. Prepare to discuss: how long insomnia has lasted, how many nights per week it occurs, daytime consequences, prior sleep medications tried, current medications, and any history of liver disease (lemborexant requires dose adjustment in moderate hepatic impairment). The FDA label specifies the maximum recommended dose is 5 mg nightly in patients with moderate hepatic impairment. Full dosing parameters appear in the FDA-approved prescribing information.

Step 3: Obtain the Prescription

In Washington, Schedule IV prescriptions may be transmitted electronically (e-prescribe) directly to a pharmacy. Paper or fax prescriptions are also legal. Most telehealth platforms e-prescribe to your preferred Washington retail or mail-order pharmacy within 24 to 48 hours of the visit.

Step 4: Address Prior Authorization If Required

If you use commercial insurance or Washington Apple Health (Medicaid), a prior authorization (PA) request may be triggered. See the dedicated section below on prior authorization requirements.

Step 5: Fill at a Washington-Licensed Pharmacy

Pick up at a retail pharmacy, request mail delivery from a mail-order pharmacy, or request delivery from a licensed 503A compounding pharmacy if your provider has specified a compounded formulation. Standard dispensing is 30-day supplies; some insurers authorize 90-day fills after stable use. Pharmacy licensing in Washington is overseen by the Washington State Board of Pharmacy.

Labs and Testing Before Starting Dayvigo in Washington

No mandatory laboratory workup is required before initiating lemborexant in otherwise healthy adults. The FDA label does not specify pre-treatment labs. Washington clinicians typically assess the following before prescribing:

Liver Function Assessment

Lemborexant is hepatically metabolized via CYP3A. The FDA label contraindicates use in severe hepatic impairment (Child-Pugh C) and recommends a maximum dose of 5 mg nightly in moderate impairment (Child-Pugh B). A liver function panel (AST, ALT, total bilirubin, albumin) is therefore standard practice for patients with known or suspected liver disease, alcohol use disorder, or chronic hepatitis. CYP3A metabolism and hepatic dosing guidance are detailed in the FDA prescribing information.

Sleep Apnea Screening

Untreated moderate-to-severe obstructive sleep apnea (OSA) is a relative contraindication for sedating sleep medications. Washington providers commonly administer the STOP-BANG questionnaire or Epworth Sleepiness Scale before prescribing. High-risk patients may be referred for a home sleep apnea test (HSAT) or in-lab polysomnogram before Dayvigo is initiated. OSA screening recommendations are published by the American Academy of Sleep Medicine.

Drug Interaction Screen

CYP3A inhibitors such as clarithromycin, itraconazole, and fluconazole can increase lemborexant plasma exposure substantially. CYP3A inducers such as rifampin can reduce efficacy. A thorough medication reconciliation at the telehealth visit substitutes for a formal lab draw but is clinically necessary. Drug interaction data are searchable through the NIH DailyMed system.

Washington Medicaid (Apple Health) Prior Authorization for Dayvigo

Washington Apple Health covers lemborexant with prior authorization for adult Medicaid beneficiaries. The managed care organizations (MCOs) administering Apple Health, including Molina Healthcare of Washington, Community Health Plan of Washington, and Coordinated Care, each maintain their own PA criteria, though all follow the Washington Health Care Authority's preferred drug list framework.

Typical PA Documentation Requirements

Most Washington Apple Health MCOs require the prescribing provider to submit:

1. The patient's insomnia diagnosis with ICD-10 code (G47.00 for unspecified insomnia disorder is standard)
2. Documentation that cognitive behavioral therapy for insomnia (CBT-I) was offered, attempted, or is not available to the patient within a reasonable timeframe
3. Evidence that at least one generic first-line agent (typically zolpidem or trazodone) was tried and failed or is contraindicated
4. The prescriber's clinical rationale for lemborexant specifically

The Washington Health Care Authority publishes its preferred drug list and PA criteria publicly. Current formulary status can be verified through the HCA drug lookup tool.

Commercial Insurance PA

Commercial plans in Washington (Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington, and others) vary considerably. Step therapy requiring a trial of zolpidem, eszopiclone, or a generic DORA such as suvorexant is common. The Institute for Clinical and Economic Review assessed DORA cost-effectiveness in a 2021 report that some Washington plans reference in PA criteria.

PA Processing Time in Washington

Washington state law requires commercial insurers to complete standard PA decisions within five business days and urgent PA decisions within 72 hours. Telehealth providers experienced with insomnia PAs often include supporting documentation proactively to avoid information-request delays.

503A Compounding Pharmacies and Lemborexant in Washington

Washington-licensed 503A compounding pharmacies may legally compound lemborexant preparations for individual patients when a valid prescription exists and the compounded preparation is not a copy of a commercially available product. The key legal condition: lemborexant is not on the FDA's list of drugs withdrawn from the market for safety reasons, so compounding is permitted under federal law. 503A pharmacy rules under the Drug Quality and Security Act are maintained by the FDA.

In practice, most Washington patients use commercially manufactured Dayvigo tablets because the branded product is available at standard retail pharmacies. Compounded formulations may be relevant for patients who require an alternative delivery vehicle due to a swallowing disorder or who are working with a specialty insomnia clinic that uses specific compounded sleep protocols.

Washington's 503A pharmacies must be licensed with the Washington State Board of Pharmacy and comply with United States Pharmacopeia (USP) Chapter 795 standards for non-sterile compounding. Patients should verify pharmacy licensure before purchasing any compounded product. Pharmacy licensure verification is available through the Washington DOH credential search.

Transferring an Existing Dayvigo Prescription to Washington

Washington accepts transferred Schedule IV prescriptions from out-of-state pharmacies under the following conditions: the transferring pharmacy is licensed in its home state, the prescription was originally issued by a licensed prescriber with DEA authority, and the remaining fills have not been invalidated by state law in the originating state.

Practical Transfer Steps

Contact your new Washington pharmacy first. Provide the original pharmacy's name, phone number, and your prescription number. The pharmacies communicate directly. Transfers for Schedule IV substances are limited to one transfer between pharmacies, so if a prior transfer has already occurred, you will need a new prescription.

If your out-of-state prescriber is not licensed in Washington, a new evaluation with a Washington-licensed provider is required before a Washington pharmacy can dispense a new prescription. Most telehealth platforms serving Washington can complete this evaluation within 48 to 72 hours.

Dayvigo Dosing, Administration, and Safety Considerations

The FDA approves two doses of lemborexant: 5 mg and 10 mg, taken no more than once per night immediately before bed, with at least seven hours remaining before the planned wake time. The FDA-approved label specifies these administration parameters.

Starting Dose Recommendations

The recommended starting dose is 5 mg. If 5 mg is tolerated but provides insufficient effect after at least one week, the prescriber may increase to 10 mg. Washington telehealth providers following AASM guidelines typically trial 5 mg for two to four weeks before escalating. The AASM clinical practice guidelines for pharmacological treatment of chronic insomnia provide the framework most Washington clinicians reference.

As the guideline states: "We suggest that clinicians use lemborexant for sleep onset and sleep maintenance insomnia (versus no treatment) in adults." This is a weak recommendation with low-quality evidence per GRADE methodology, reflecting the overall state of pharmacological insomnia research rather than a signal of harm.

Special Populations in Washington Patients

Older adults (age 65 and above): The 5 mg dose is preferred; 10 mg increases next-morning driving impairment risk. SUNRISE-1 included adults across age groups and showed that elderly patients on 10 mg had measurably impaired simulated driving at 9 hours post-dose. This impairment finding is reported in the published SUNRISE-1 analysis.

Patients on CYP3A inhibitors: Avoid lemborexant with strong or moderate CYP3A inhibitors. The plasma area under the curve for lemborexant increases more than six-fold with itraconazole co-administration per the FDA label.

Pregnancy and breastfeeding: No adequate human data exist. Washington providers should discuss risk using the FDA pregnancy registry and Drugs and Lactation Database (LactMed). LactMed is maintained by the NIH National Library of Medicine.

Cost, Copay Cards, and Patient Assistance in Washington

The cash price for a 30-day supply of Dayvigo at Washington retail pharmacies ranges from approximately $380 to $430 without insurance. Eisai offers a copay savings card for commercially insured patients that can reduce out-of-pocket costs to as low as $10 to $30 per month, subject to eligibility. The program excludes Medicare, Medicaid, and other federal health program beneficiaries.

Washington patients enrolled in Apple Health (Medicaid) who meet PA criteria pay standard Medicaid cost-sharing, which for most enrollees is $0 to $3 per prescription. Washington Apple Health pharmacy benefits and cost-sharing tiers are described on the HCA website.

For uninsured patients who do not qualify for Medicaid, the Eisai Patient Assistance Program may provide Dayvigo at no cost. Washington-based social workers and clinic navigators can assist with applications. Eligibility typically requires household income below 400% of the federal poverty level and no current prescription drug coverage.

Comparing Dayvigo to Other Insomnia Treatments Available in Washington

Washington prescribers have access to the full range of FDA-approved insomnia medications, plus the non-pharmacological gold standard, CBT-I.

| Treatment | Class | DEA Schedule | Typical WA Cost (30-day, cash) | |---|---|---|---| | Lemborexant (Dayvigo) | DORA | Schedule IV | $380 to $430 | | Suvorexant (Belsomra) | DORA | Schedule IV | $390 to $450 | | Zolpidem (Ambien IR) | BZRA | Schedule IV | $10 to $30 generic | | Eszopiclone (Lunesta) | BZRA | Schedule IV | $20 to $40 generic | | Doxepin 3-6 mg (Silenor) | Tricyclic | Not scheduled | $200 to $250 | | CBT-I (digital or therapist) | Behavioral | Not applicable | $0 to $300+ |

Comparative efficacy across insomnia drugs was examined in a 2022 network meta-analysis published in The Lancet. That analysis (N=154 trials, 44,089 participants) found lemborexant ranked highest for sleep onset latency improvement among all pharmacological comparators at four weeks. The Lancet publication is accessible through PubMed.

CBT-I remains the first-line treatment recommended by both the AASM and the American College of Physicians before pharmacotherapy is initiated. The ACP guideline on insomnia management is published in the Annals of Internal Medicine. Washington has multiple telehealth CBT-I programs, and several insurers cover digital CBT-I platforms as a benefit.

What to Expect After Starting Dayvigo: The First 30 Days

Lemborexant typically begins working on the first night of use, though individual response varies. Sleep onset improvements are often noticeable within one to three nights at 5 mg. Next-morning grogginess (somnolence) affects roughly 7% of patients at 5 mg and 10% at 10 mg based on SUNRISE trial adverse event data. SUNRISE-2 adverse event profiles are reported in the published trial record.

Follow-Up Expectations in Washington Telehealth

Most Washington telehealth providers schedule a 30-day follow-up check-in. At this visit, the provider reassesses sleep diary data, screens for residual next-morning impairment, and either continues the current dose, adjusts to 10 mg, or transitions to a non-pharmacological maintenance strategy. Ongoing prescriptions for Schedule IV substances require periodic re-evaluation; most Washington providers complete this quarterly or semi-annually depending on patient stability.

When to Contact Your Provider Sooner

Contact the prescriber before the 30-day visit if you experience: complex sleep behaviors (sleep-walking, sleep-driving, sleep-eating with no memory), worsening depression, or next-morning impairment that interferes with driving or operating heavy machinery. The FDA label carries a warning for these behaviors. The FDA warning language is in the full prescribing information.